DAX25.427 +0,1%Est506.022 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,34 +1,4%Nas23.734 +0,3%Bitcoin78.921 +1,0%Euro1,1656 -0,1%Öl65,13 +1,3%Gold4.604 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 DroneShield A2DMAA RENK RENK73 Deutsche Telekom 555750 Siemens Energy ENER6Y Infineon 623100 Lufthansa 823212 Allianz 840400 Amazon 906866 BioNTech (ADRs) A2PSR2 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX stabil -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- JPMorgan, Siemens Energy, BioNTech, Rüstungsaktien, DEUTZ, Zalando, Munich Re, DroneShield, Nordex im Fokus
Top News
Jefferies & Company Inc. beurteilt Airbus SE-Aktie mit Buy Jefferies & Company Inc. beurteilt Airbus SE-Aktie mit Buy
Zcash nach Korrektur fast verdoppelt: Technische Signale stützen bullische Prognose Zcash nach Korrektur fast verdoppelt: Technische Signale stützen bullische Prognose
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Verteidigung als Anlagechance: Mit diesem ETF erhältst du Zugang zu europäischen Unternehmen aus dem Luft-, Raumfahrt- und Verteidigungssektor

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
188,80 EUR +0,20 EUR +0,11 %
STU
220,18 USD +0,10 USD +0,05 %
vorbörslich
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.333,53 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
PR NewswireSKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
PR NewswireHealth Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR NewswireAbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
PR NewswireAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
PR NewswireAbbVie to Host Second-Quarter 2023 Earnings Conference Call
PR NewswireAbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
PR NewswireAbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally
PR NewswireAbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
MyDividendsAbbVie zahlt eine konstante Dividende an die Investoren
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireRisankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
PR NewswireAbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
PR NewswireAbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program
PR NewswireAbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswirePhase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
PR NewswireNew England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
PR NewswireAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
PR NewswireEPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
PR NewswireU.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
PR NewswireHealth Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
PR NewswireAbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
PR NewswireAbbVie to Present at the Bank of America Securities Healthcare Conference
PR NewswireAbbVie Reports First-Quarter 2023 Financial Results
PR NewswireAbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 ...
PR NewswireU.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
PR NewswireAbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
PR NewswireAbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
PR NewswireAbbVie to Host First-Quarter 2023 Earnings Conference Call
PR NewswireCoolSculpting® Elite Announces First Ever CoolMonth
PR NewswireAllergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireAbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
PR NewswireRisankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
PR NewswireAbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
PR NewswireAbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor T...
PR NewswireAbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema
PR NewswireAbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.